

# Late Stage Pipeline – Pharma & Vaccines

Phase III		Registration	
<b>Lantus®</b> insulin glargine Reduction in CV morbidity & mortality	N	<b>BSI-201</b> PARP inhibitor Triple Negative Breast Cancer	N
<b>AVE0010</b> GLP-1 agonist Type 2 diabetes	N	<b>aflibercept (VEGF-Trap)</b> Combo: 1st line mProstate; 2nd line NSCLC; 2nd line mCRC	N
<b>XRP0038</b> NV1FGF Critical Limb Ischemia (CLI)	N	<b>cabazitaxel</b> Taxoid - Tubulin inhibitor Prostate cancer	N
<b>teriflunomide</b> immunomodulator Multiple Sclerosis (monotherapy)	N	<b>larotaxel</b> Taxoid - Tubulin inhibitor Pancreatic cancer, Bladder cancer	N
<b>AVE5026</b> Indirect Xa/IIa inhibitor VTE prevent. in ortho, abdo. surgery, cancer patients	N	<b>AVE8062</b> Vascular disrupting agent Sarcoma	N
<b>idrabiotaparinux</b> Biotinylated long-acting pentasaccharide; Indirect Xa inhibitor Long-term treatment DVT/PE; AF	N	<b>alvocidib</b> Cyclin-dependent kinase inhibitor CLL	N
<b>otamixaban</b> Direct Xa inhibitor ACS	N	<b>Taxotere®</b> docetaxel Pediatric	
<b>Plavix®</b> clopidogrel bisulfate AF U.S.; Pedi. extension; ACS high loading dose; Stent, & PAD, Japan		<b>Xatral®</b> alfuzosin Pediatric	
<b>Lovenox®</b> enoxaparin Pen		<b>Actonel®</b> risedronate Pediatric, EU	
		<b>Menactra®</b> Meningococcal disease Infant / Toddler 9-12 months	
		<b>Adacel®</b> Diphtheria, tetanus and pertussis 4-6 years of age	
		<b>Flu ID</b> Seasonal influenza vaccine Intradermal micro-injection, U.S.	
		<b>Hexaxim™</b> DTP-HepB-Polio-Hib vaccine	
		<b>Pediacel® EU</b> DTP-Polio-Hib vaccine	
		<b>HIV</b> Prophylaxis Proof of concept in Thailand	
		<b>Multaq®</b> dronedarone Atrial fibrillation, EU	N
		<b>Cilityri®</b> eplivanserin 5-HT <sub>2A</sub> antagonist - Insomnia	N
		<b>Plavix®</b> clopidogrel bisulfate Combo ASA, EU; AF, EU	
		<b>Allegra®</b> fexofenadine Orally Disintegrating Tablets, Japan	
		<b>Flu High Dose IM</b> Seasonal influenza vaccine High-dose IM injection, U.S.	
		<b>IMOJEV™</b> Japanese Encephalitis single-dose vaccine	
		<b>Panenza™</b> Non-adjuvanted Flu Pandemic EU (H1N1)	
		<b>Humenza™</b> Adjuvanted Flu Pandemic EU (H1N1)	

## Pharmaceuticals

**N** New Molecular Entity

## Therapeutic area

- Metabolic Disorders
- Cardiovascular
- Central Nervous System
- Oncology
- Thrombosis
- Internal Medicine
- Vaccines